NuProbe and AcornMed Reach a Strategic Collaboration to Develop Minimal Residual Disease Detection Products with BDA technology
NuProbe and AcornMed Reach a Strategic Collaboration to Develop Minimal Residual Disease Detection Products with BDA technology News provided by Share this article Share this article HOUSTON and BEIJING, April 27, 2021 /PRNewswire/ -- NUPROBE GLOBAL, a molecular diagnostics company based in Shanghai, China and Houston, Texas, has reached a strategic collaboration agreement with AcornMed Biotechnology Co., Ltd. (AcornMed). The two companies have agreed to work together to develop products for minimal residual disease (MRD) detection in genitourinary tract cancer and hematological cancer usin...
Source: prnewswire.com